For appropriately selected patients with muscle-invasive bladder cancer, preserving the bladder can be a curative treatment ...
International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European ...
KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.
FDA approved adjuvant atezolizumab for post-cystectomy MIBC with ctDNA MRD positivity, alongside Signatera CDx as the required companion diagnostic for eligibility determination. IMvigor011 randomized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results